HFR Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

HFR Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,000	Closed	-$136K	–	62
2023 Q1	$136K	Hold	20,000	–	–	0.04%	61
2022 Q4	$148K	Hold	20,000	–	–	0.04%	63
2022 Q3	$198K	Hold	20,000	–	–	0.06%	53
2022 Q2	$218K	Hold	20,000	–	–	0.07%	55
2022 Q1	$226K	Hold	20,000	–	–	0.06%	59
2021 Q4	$314K	Hold	20,000	–	–	0.08%	49
2021 Q3	$343K	Hold	20,000	–	–	0.1%	47
2021 Q2	$430K	Buy	+20,000	New	+$358K	0.13%	43

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

HFR Wealth Management's VNDA Position: Q2 2023 in Review

HFR Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2023, closing a stake of 20,000 shares — an estimated $136K sold.

HFR Wealth Management first reported a position in VNDA in Q2 2021 and held it in 8 quarters. The position peaked at $430K in Q2 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q2 2023.

HFR Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
HFR Wealth Management sold 20,000 Vanda Pharmaceuticals shares in Q2 2023, an estimated $136K.
HFR Wealth Management first reported a position in Vanda Pharmaceuticals in Q2 2021 and held it in 8 quarters.
HFR Wealth Management's Vanda Pharmaceuticals position peaked at $430K in Q2 2021.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2023.

Based on HFR Wealth Management's 13F filing for Q2 2023, filed 7 Aug 2023.